{"classes":[{"categories":[{"measurements":[{"comment":"Data not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"52.6","upperLimit":"NA","value":"58.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"}],"units":"Participants"}],"title":"CLL/SLL"},{"categories":[{"measurements":[{"comment":"Data not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"31.34","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"}],"units":"Participants"}],"title":"WM"},{"categories":[{"measurements":[{"comment":"Data not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"16.2","upperLimit":"NA","value":"28.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"title":"MCL"},{"categories":[{"measurements":[{"comment":"Data not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"6.5","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"MZL"},{"categories":[{"measurements":[{"comment":"Data not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"8.3","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"title":"FL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"26.2","value":"14.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"DLBCL"},{"categories":[{"measurements":[{"comment":"Data not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"5.9","upperLimit":"NA","value":"25.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"RT"},{"categories":[{"measurements":[{"comment":"Data not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"HCL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"378"}],"units":"Participants"}],"description":"DOR for responders is defined as time from the date of the earliest qualifying response to the date of progressive disease or death for any cause, whichever occurs earlier. Efficacy results are reported for responders (defined as PR or better, except CLL/SLL and WM) in each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; PR with lymphocytosis or better), Waldenstrom macroglobulinemia (WM; minor response or better), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).","dispersionType":"95% Confidence Interval","groups":[{"description":"The dose regimens from Part 1 (40 mg, 80 mg, 160 mg QD, 160 mg BID and 320 mg QD) and Part 2 (160 mg BID and 320 mg QD) were evaluated in different disease types. Efficacy evaluations are reported by disease type for Parts 1 and 2 combined, as pre-specified in the statistical analysis plan.","id":"OG000","title":"Part 1 and Part 2: Overall"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable Set consists of all participants who received at least one dose of zanubrutinib; for WM, participants also must have a baseline IgM (or M-protein) ≥ 5 g/L and no prior exposure to a BTK inhibitor.","reportingStatus":"POSTED","timeFrame":"Up to 6 years and 7 months","title":"Part 1 and Part 2: Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}